Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research report released on Wednesday. The firm issued a hold rating on the medical research company’s stock.

Separately, BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Accelerate Diagnostics Trading Down 0.8 %

Shares of AXDX opened at $1.26 on Wednesday. The firm’s fifty day simple moving average is $1.25 and its two-hundred day simple moving average is $1.54. Accelerate Diagnostics has a 12 month low of $0.73 and a 12 month high of $2.09. The stock has a market capitalization of $31.55 million, a P/E ratio of -0.44 and a beta of 0.61.

Insiders Place Their Bets

In other news, Director John Patience purchased 200,000 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were acquired at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the completion of the acquisition, the director now owns 653,224 shares in the company, valued at approximately $1,025,561.68. The trade was a 44.13 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 43.60% of the company’s stock.

Hedge Funds Weigh In On Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics at the end of the most recent quarter. 17.14% of the stock is currently owned by hedge funds and other institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.